TUCSON, Ariz., November 18, 2019-- UAVenture Capital Fund (UAVC), a Tucson-based venture capital fund dedicated to the commercialization of University of Arizona discoveries, products, technologies and services, today announced its thirteenth investment. The Fund has invested in StimAire, Inc. where breakthrough technology may revolutionize the treatment for Obstructive Sleep Apnea (OSA). StimAire replaces today's surgically implanted neural stimulation devices with a small wearable and a tiny injectable device. The technology will eliminate major surgery and associated complications, risks, and costs.